High immunoglobulin E level is associated with increased readmission in children with bronchopneumonia

Abstract

Background: Increased immunoglobulin E (IgE) is associated with lower respiratory tract infections. The study aimed to evaluate the association between IgE and the rate of bronchopneumonia-related readmission within 12 months in children. Methods: A total of 1099 children aged over 1 year with bronchopneumonia, from 1 January 2015 to 31 December 2016, were enrolled. Unplanned readmissions within 12 months after discharge were observed. Multivariate regression analysis was used to identify independent risk factors for rehospitalization. Results: The rate of rehospitalization was 11.4% (125/1099). Compared to the nonreadmission children, IgE levels, the proportion of children with asthma and hospitalization duration were significantly higher in the readmission children ( p < 0.05). Compared to the children with normal IgE (≤ 165 IU/ml) levels, the risk of rehospitalization was significantly higher in children with abnormal IgE [odds ratio (OR) 1.781, 95% confidence interval (CI) 1.209–2.624, p = 0.004]. Children with IgE level more than three times the upper limit had even higher risks of readmission (OR 2.037, 95%CI 1.172–3.540, p = 0.012). Meanwhile, the risk of readmission in children with abnormal IgE combined with or without bronchial asthma was significantly higher (OR 2.548 and 1.918, 95% CI 1.490–4.358 and 1.218–3.020, p = 0.001 and 0.005, respectively). Conclusions: Children aged over 1 year with bronchopneumonia who had higher IgE levels are at increased risk for rehospitalization within the first 12 months of the index hospitalization and IgE level may be used as a predictor of rehospitalization in children with bronchopneumonia.

Prediction of Bronchopneumonia Inpatients’ Total Hospitalization Expenses Based on BP Neural Network and Support Vector Machine Models

“…Bronchopneumonia is a severe disease that threatens people's health in China. It is also a disease that accounts for a large proportion of the spectrum of hospitalized infections [ 3 , 4 ]. Bronchopneumonia is often caused by bacteria, viruses, molds, mycoplasma pneumonia, and other pathogens.…”

The therapeutic effects of naringenin on bronchial pneumonia in children

“…Bronchial pneumonia, also known as lobular pneumonia, is a common infectious disease in children, especially in toddlers and infants 1 . Bronchial pneumonia in children often occurs in winter and spring, when the weather is cold and unpredictable.…”

Effects of four types of chinese medicines as concomitant drugs with azithromycin for the treatment of mycoplasma pneumonia in children in China: a network meta-analysis

“…Mycoplasma pneumonia in children (MPC) is mild or absent in the early stage, but the disease progresses rapidly, and extrapulmonary complications are diverse 1,2 . The first choice of antibacterial drugs is macrolides, which are represented by azithromycin 3,4 .…”